Therapeutic potential of the SARMs: revisiting the androgen receptor for drug discovery

Authors: Segal, Scott; Narayanan, Ramesh; Dalton, James T

Source: Expert Opinion on Investigational Drugs, Volume 15, Number 4, 1 April 2006 , pp. 377-387(11)

Buy & download fulltext article:

Price: $99.00 plus tax (Refund Policy)

Abstract:

Selective androgen receptor modulators (SARMS) bind to the androgen receptor and demonstrate anabolic activity in a variety of tissues; however, unlike testosterone and other anabolic steroids, these nonsteroidal agents are able to induce bone and muscle growth, as well as shrinking the prostate. The potential of SARMS is to maximise the positive attributes of steroidal androgens as well as minimising negative effects, thus providing therapeutic opportunities in a variety of diseases, including muscle wasting associated with burns, cancer, end-stage renal disease, osteoporosis, frailty and hypogonadism. This review summarises androgen physiolology, the current status of the R&D of SARMS and potential therapeutic indications for this emerging class of drugs.

Keywords: androgen; hypogonadism; muscle wasting; osteoporosis; steroid

Document Type: Review article

DOI: http://dx.doi.org/10.1517/13543784.15.4.377

Publication date: 2006-04-01

More about this publication?